Cargando…
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
BACKGROUND: Intraperitoneal (IP) perioperative chemotherapy with cisplatin is an interesting option in ovarian cancer treatment. A combination of cisplatin with IP epinephrine (already shown to improve IP and decrease systemic platinum (Pt) exposure) was evaluated using a population pharmacokinetic...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273361/ https://www.ncbi.nlm.nih.gov/pubmed/22173671 http://dx.doi.org/10.1038/bjc.2011.557 |
_version_ | 1782222925799096320 |
---|---|
author | Royer, B Kalbacher, E Onteniente, S Jullien, V Montange, D Piedoux, S Thiery-Vuillemin, A Delroeux, D Pili-Floury, S Guardiola, E Combe, M Muret, P Nerich, V Heyd, B Chauffert, B Kantelip, J-P Pivot, X |
author_facet | Royer, B Kalbacher, E Onteniente, S Jullien, V Montange, D Piedoux, S Thiery-Vuillemin, A Delroeux, D Pili-Floury, S Guardiola, E Combe, M Muret, P Nerich, V Heyd, B Chauffert, B Kantelip, J-P Pivot, X |
author_sort | Royer, B |
collection | PubMed |
description | BACKGROUND: Intraperitoneal (IP) perioperative chemotherapy with cisplatin is an interesting option in ovarian cancer treatment. A combination of cisplatin with IP epinephrine (already shown to improve IP and decrease systemic platinum (Pt) exposure) was evaluated using a population pharmacokinetic analysis. METHODS: Data from 55 patients treated with cisplatin-based IP perioperative chemotherapy with (n=26) or without (n=29) epinephrine were analysed using NONMEM. RESULTS: Epinephrine halves clearance between peritoneum and serum (IPCL) and increases the Pt central volume of distribution, IP exposure and penetration in tissue. IPCL has a better predictive value than any other parameter with respect to renal toxicity. CONCLUSION: This confirms that IPCL could be useful in assessing renal toxicity. As IPCL is also linked to tissue penetration and IP exposure, it may be proposed as biomarker. In addition to a Bayesian estimation, we propose a single-sample calculation-way to assess it. Prospective studies are needed to validate IPCL as a biomarker in this context. |
format | Online Article Text |
id | pubmed-3273361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-32733612013-01-31 Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study Royer, B Kalbacher, E Onteniente, S Jullien, V Montange, D Piedoux, S Thiery-Vuillemin, A Delroeux, D Pili-Floury, S Guardiola, E Combe, M Muret, P Nerich, V Heyd, B Chauffert, B Kantelip, J-P Pivot, X Br J Cancer Clinical Studies BACKGROUND: Intraperitoneal (IP) perioperative chemotherapy with cisplatin is an interesting option in ovarian cancer treatment. A combination of cisplatin with IP epinephrine (already shown to improve IP and decrease systemic platinum (Pt) exposure) was evaluated using a population pharmacokinetic analysis. METHODS: Data from 55 patients treated with cisplatin-based IP perioperative chemotherapy with (n=26) or without (n=29) epinephrine were analysed using NONMEM. RESULTS: Epinephrine halves clearance between peritoneum and serum (IPCL) and increases the Pt central volume of distribution, IP exposure and penetration in tissue. IPCL has a better predictive value than any other parameter with respect to renal toxicity. CONCLUSION: This confirms that IPCL could be useful in assessing renal toxicity. As IPCL is also linked to tissue penetration and IP exposure, it may be proposed as biomarker. In addition to a Bayesian estimation, we propose a single-sample calculation-way to assess it. Prospective studies are needed to validate IPCL as a biomarker in this context. Nature Publishing Group 2012-01-31 2011-12-15 /pmc/articles/PMC3273361/ /pubmed/22173671 http://dx.doi.org/10.1038/bjc.2011.557 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Studies Royer, B Kalbacher, E Onteniente, S Jullien, V Montange, D Piedoux, S Thiery-Vuillemin, A Delroeux, D Pili-Floury, S Guardiola, E Combe, M Muret, P Nerich, V Heyd, B Chauffert, B Kantelip, J-P Pivot, X Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study |
title | Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study |
title_full | Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study |
title_fullStr | Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study |
title_full_unstemmed | Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study |
title_short | Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study |
title_sort | intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study |
topic | Clinical Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273361/ https://www.ncbi.nlm.nih.gov/pubmed/22173671 http://dx.doi.org/10.1038/bjc.2011.557 |
work_keys_str_mv | AT royerb intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT kalbachere intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT ontenientes intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT jullienv intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT montanged intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT piedouxs intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT thieryvuillemina intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT delroeuxd intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT piliflourys intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT guardiolae intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT combem intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT muretp intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT nerichv intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT heydb intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT chauffertb intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT kantelipjp intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy AT pivotx intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy |